COSCIENS Biopharma (CSCI) 6-K 10 May 22 Current report (foreign) Financial data

Cover

Cover	3 Months Ended
	Mar. 31, 2022
Cover [Abstract]
Document Type	6-K
Amendment Flag	false
Document Period End Date	Mar. 31, 2022
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2022
Current Fiscal Year End Date	--12-31
Entity File Number	001-38064
Entity Registrant Name	Aeterna Zentaris Inc.
Entity Central Index Key	0001113423
Entity Address, Address Line One	c/o Norton Rose Fulbright Canada, LLP
Entity Address, Address Line Two	222 Bay Street
Entity Address, Address Line Three	Suite 3000, PO Box 53
Entity Address, City or Town	Toronto
Entity Address, Country	CA
Entity Address, Postal Zip Code	M5K 1E7

Condensed Interim Consolidated

Condensed Interim Consolidated Statements of Financial Position - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Current assets
Cash and cash equivalents	$ 63,596	$ 65,300
Trade and other receivables (note 4)	693	1,314
Inventory	278	73
Income taxes receivable	1,480	2,361
Prepaid expenses and other current assets (note 5)	1,050	1,772
Total current assets	67,097	70,820
Restricted cash equivalents	330	335
Right of use assets	153	150
Property, plant and equipment	45	42
Other non-current assets	130
Identifiable intangible assets	612	625
Goodwill	7,977	8,130
Total Assets	76,344	80,102
Current liabilities
Payables and accrued liabilities (note 6)	2,795	2,672
Current portion of provisions	34	34
Income taxes payable	112	115
Current portion of deferred revenues (note 3)	2,582	4,815
Current portion of lease liabilities	143	130
Total current liabilities	5,666	7,766
Deferred revenues (note 3)	2,783	1,493
Deferred gain	96	98
Lease liabilities	22	31
Employee future benefits (note 7)	14,386	17,485
Provisions	232	243
Total liabilities	23,185	27,116
SHAREHOLDERS’ EQUITY
Share capital (note 8)	293,410	293,410
Warrants (note 8)	5,085	5,085
Other capital (note 8)	89,815	89,788
Deficit	(334,510)	(334,619)
Accumulated other comprehensive loss (“AOCI”)	(641)	(678)
Total shareholders’ equity	53,159	52,986
Total liabilities and shareholders’ equity	$ 76,344	$ 80,102

Condensed Interim Consolidate_2

Condensed Interim Consolidated Statements of Changes in Shareholders' Equity - USD ($) $ in Thousands	Issued capital [member]	Warrants [Member]	Other equity interest [member]	Retained earnings [member]	Accumulated Other Comprehensive Loss Income [Member]	Total
Balance - January 1, 2021 at Dec. 31, 2020	$ 235,008	$ 12,402	$ 89,505	$ (322,659)	$ (1,045)	$ 13,211
Balance, shares at Dec. 31, 2020	62,678,613
IfrsStatementLineItems [Line Items]
Net loss (as restated note 1)				(1,458)		(1,458)
Foreign currency translation adjustments					547	547
Actuarial gain on defined benefit plans				882		882
Comprehensive loss				(576)	547	(29)
Share-based compensation costs			13			13
Issuance of common shares, net of transaction costs	$ 29,082	1,897				30,979
Issuance of common shares, net of transaction costs, shares	23,586,207
Exercise of warrants	$ 29,691	(9,704)				19,987
Exercise of warrants, shares	34,888,965
Balance – March 31, 2021 at Mar. 31, 2021	$ 293,781	4,595	89,518	(323,235)	(498)	64,161
Balance, shares at Mar. 31, 2021	121,153,785
Balance - January 1, 2021 at Dec. 31, 2021	$ 293,410	5,085	89,788	(334,619)	(678)	52,986
Balance, shares at Dec. 31, 2021	121,397,007
IfrsStatementLineItems [Line Items]
Net loss (as restated note 1)				(2,640)		(2,640)
Foreign currency translation adjustments					37	37
Actuarial gain on defined benefit plans				2,749		2,749
Comprehensive loss				109	37	146
Share-based compensation costs			27			27
Balance – March 31, 2021 at Mar. 31, 2022	$ 293,410	$ 5,085	$ 89,815	$ (334,510)	$ (641)	$ 53,159
Balance, shares at Mar. 31, 2022	121,397,007

Condensed Interim Consolidate_3

Condensed Interim Consolidated Statements of Comprehensive Income (Loss) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Revenues (note 3)
License fees	$ 432	$ 524
Development services	966	1,095
Product sales	57
Royalties	19	8
Supply chain	43	41
Total revenues	1,517	1,668
Operating expenses
Cost of sales	79	29
Research and development expenses	2,390	1,458
General and administrative expenses	1,558	1,264
Selling expenses	303	246
Total operating expenses (note 9)	4,330	2,997
Loss from operations	(2,813)	(1,329)
Gains (loss) due to changes in foreign currency exchange rates	174	(248)
Other finance costs	(1)	(10)
Net finance income (costs)	173	(258)
Loss before income taxes	(2,640)	(1,587)
Income tax recovery		129
Net loss	(2,640)	(1,458)
Items that may be reclassified subsequently to profit or loss:
Foreign currency translation adjustments	37	547
Items that will not be reclassified to profit or loss:
Actuarial gain on defined benefit plans (note 7)	2,749	882
Comprehensive income (loss)	$ 146	$ (29)
Net loss per share [basic and diluted]	$ (0.02)	$ (0.02)
Weighted average number of shares outstanding (note 12):
Basic	121,397,007	95,444,990
Diluted	121,397,007	95,444,990

Condensed Interim Consolidate_4

Condensed Interim Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Cash flows from operating activities
Net loss for the period	$ (2,640)	$ (1,458)
Items not affecting cash and cash equivalents:
Provision	(2)	19
Depreciation and amortization	36	36
Share-based compensation costs	27	13
Employee future benefits (note 7)	99	49
Amortization of deferred revenues	(828)	(524)
Foreign exchange on items denominated in foreign currencies	(174)	266
Other non-cash items	14	31
Receipt of income taxes receivable	881	(1,124)
Changes in operating assets and liabilities (note 10)	1,126	1,647
Net cash used in operating activities	(1,461)	(1,045)
Cash flows from financing activities
Issuance of common shares (note 8)		34,200
Transaction costs (note 8)		(3,221)
Proceeds from exercise of warrants (note 8)		19,987
Payments on lease liabilities	(34)	(33)
Net cash (used in) provided by financing activities	(34)	50,933
Cash flows from investing activities
Purchase of intangible assets		(490)
Purchase of property and equipment	(6)	(17)
Net cash used in investing activities	(6)	(507)
Effect of exchange rate changes on cash and cash equivalents	(203)	(281)
Net change in cash and cash equivalents	(1,704)	49,100
Cash and cash equivalents – Beginning of period	65,300	24,271
Cash and cash equivalents – End of period	$ 63,596	$ 73,371

Business overview

Business overview	3 Months Ended
	Mar. 31, 2022
Business overview	1. Business overview Summary of business Aeterna Zentaris (the “Company” or “Aeterna”) is a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests. The Company’s lead product, Macrilen™ (macimorelin), is the first and only U.S. Food and Drug Administration (“FDA”) and European Medicines Agency-approved oral test indicated for the diagnosis of patients with adult growth hormone deficiency (“AGHD”). Macrilen™ is currently marketed in the US through a license agreement (the “Novo Amendment”) between the Company and Novo Nordisk Health Care AG (“Novo”) and in the United Kingdom and Europe through a license agreement with Consilient Healthcare Inc (the “Consilient” or “CH”) under the trade name of Ghryvelin®. The Company is also dedicated to the development of therapeutic assets and has recently taken steps to establish a pre-clinical pipeline to potentially address unmet medical needs across a number of indications with a focus on rare or orphan indications and with the potential for pediatric use. These unaudited condensed interim consolidated financial statements were approved by the Board of Directors (the “Board”) on May 10, 2022. Basis of presentation These unaudited condensed interim consolidated financial statements have been prepared in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board (“IFRS”) applicable to the preparation of interim financial statements, including IAS 34, Interim Financial Reporting. These unaudited condensed interim consolidated financial statements should be read in conjunction with the Company’s annual consolidated financial statements as at and for the year ended December 31, 2021. The accounting policies in these condensed interim consolidated financial statements are consistent with those presented in the Company’s annual consolidated financial statements, with the exception of the Company’s policy with respect to the government assistance which is as follows: Government assistance Amounts received or receivable resulting from government assistance programs, including grants and refundable investment tax credits for research and development, are accounted for in accordance with IAS 20 NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS AS AT MARCH 31, 2022 AND FOR THE THREE MONTHS ENDED MARCH 31, 2022 AND 2021 (amounts in thousands of US dollars, except share and per share data and as otherwise noted) (Unaudited) COVID-19 & Russia and Ukraine conflict The rise in COVID-19 variants has caused delays in site initiation and patient enrollment in our DETECT-trial and may be impacting sales activities for Macrilen™ in the US. Further, the continuation of the COVID-19 pandemic and the Russia/Ukraine conflict may also cause some patients to be unwilling to enroll in our trials or be unable to comply with clinical trial protocols if such events impede patient movement or interrupt healthcare services, both of which would delay our ability to conduct clinical trials or release clinical trial results on a timely basis and could delay our ability to obtain regulatory approval and commercialize our product candidates. For the period ended March 31, 2022, the Company assessed the impact of the uncertainties around the COVID-19 pandemic and the Russia/Ukraine conflict on its judgments, estimates, accounting policies and amounts recognized in these unaudited condensed interim consolidated financial statements and determined that no adjustments were required to the carrying value of assets and liabilities. Management determined that the recruitment for the DETECT-trial may now continue until later into 2023 compared to the end of the 2022 year as anticipated at the end of the previous fiscal year. As such, an amount of $ 1.2 million of deferred revenue has been reclassified from current to long-term portion as of March 31, 2022 to reflect the revised timeline. We are currently assessing with Novo the impact on timelines and study cost. The Company will continue to monitor the impact of the development of the COVID-19 pandemic and Russia/Ukraine conflict in further reporting periods. Actual results could differ from these estimates, and such differences may be material. Restatement of comparative period figures At the end of the prior fiscal year2021, the Company restated its previously reported condensed consolidated interim financial statements for the three-month period ended March 31, 2021 and the three-month and six-month periods ended June 30, 2021 and three-month and nine-month periods ended September 30, 2021 with respect to the recognition of revenue for the Novo Amendment, signed in November 2020. During the fourth quarter of 2021, management reassessed the classification of the development activities associated with the DETECT-trial and concluded that subsequent to the Novo Amendment, the parties no longer shared joint control of these activities and, as such, these development activities no longer met the definition of a joint operation, as defined in IFRS 11 IFRS 15 NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS AS AT MARCH 31, 2022 AND FOR THE THREE MONTHS ENDED MARCH 31, 2022 AND 2021 (amounts in thousands of US dollars, except share and per share data and as otherwise noted) (Unaudited) The condensed interim consolidated financial statements were not adjusted and refiled at the time of discovery of the error, rather the comparatives are being corrected now with the filing of the interim financials for the period ended March 31, 2022. The impacts of the March 31, 2021 restatements are as follows (amounts in thousands, except for basic and diluted loss per share): Disclosure of Restatements

Critical accounting estimates a

Critical accounting estimates and judgements	3 Months Ended
	Mar. 31, 2022
Critical accounting estimates and judgements	2. Critical accounting estimates and judgements The preparation of condensed interim consolidated financial statements in accordance with IFRS requires management to make judgments, estimates and assumptions that affect the reported amounts of the Company’s assets, liabilities, revenues, expenses and related disclosures. Judgments, estimates and assumptions are based on historical experience, expectations, current trends and other factors that management believes to be relevant at the time at which the Company’s condensed interim consolidated financial statements are prepared. Management reviews, on a regular basis, the Company’s accounting policies, assumptions, estimates and judgments in order to ensure that the condensed interim consolidated financial statements are presented fairly and in accordance with IFRS applicable to interim financial statements. Critical accounting estimates and assumptions, as well as critical judgments used in applying accounting policies in the preparation of the Company’s condensed interim consolidated financial statements, were the same as those applied to the Company’s annual consolidated financial statements as at and for the year ended December 31, 2021 and December 31, 2020 and for the years ended December 31, 2021, and 2020.

License and supply arrangements

License and supply arrangements	3 Months Ended
	Mar. 31, 2022
License and supply arrangements	3. License and supply arrangements On January 16, 2018, the Company, through AEZS Germany, entered into License Agreement with Strongbridge Ireland Limited (“Strongbridge”) to carry out development, manufacturing, registration, regulatory and supply chain services for the commercialization of Macrilen™ (macimorelin) in the U.S. and Canada. Effective December 19, 2018, Strongbridge sold the entity which owned the License Agreement for the U.S. and Canadian rights to Macrilen™ (macimorelin) to Novo Nordisk Biopharm Ltd. Ireland (Novo). In 2019, the Interim Supply Arrangement was concluded and Novo contracted AEZS Germany to provide supply chain services for the manufacture of Macrilen™ (macimorelin). On November 16, 2020, the Company, through AEZS Germany, entered into Novo Amendment of its existing License Agreement with Novo related to the development and commercialization of macimorelin. The Company earns license fees, product sales, royalties and supply chain revenue, in addition to development service revenue from conducting the Study P02, from Novo. NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS AS AT MARCH 31, 2022 AND FOR THE THREE MONTHS ENDED MARCH 31, 2022 AND 2021 (amounts in thousands of US dollars, except share and per share data and as otherwise noted) (Unaudited) In June 2020, the Company entered into an exclusive distribution and quality agreement with MegaPharm Ltd. (“MegaPharm”) for the commercialization in Israel and in the Palestinian Authority of macimorelin to be used in the diagnosis of patients with adult growth hormone deficiency and in clinical development for the diagnosis of pediatric growth hormone deficiency (the “MegaPharm Agreement”). As of March 31, 2022, there have been no products supplied under this agreement. On December 7, 2020, the Company entered into an exclusive licensing agreement with Consilient Health Limited (“CH”) for the commercialization of macimorelin (the “Licensed Product”) in the European Economic Area and the United Kingdom (the “CH License Agreement”). The Company earns licenses fees and product sale revenue from CH. The Company and NK Meditech Limited (“NK”) entered into a licensing agreement, effective November 30, 2021 and pursuant to which the Company granted to NK the exclusive right to commercialize (including marketing, selling and offering to sell) macimorelin in the Republic of Korea (the “ROK”) and as applicable, in the Democratic People’s Republic of Korea (“DPRK”) to the extent NK is allowed to use the aforementioned licensed rights in the latter (“NK License Agreement”). As of March 31, 2022, there have been no products supplied under this agreement. The following table provides a summary of deferred revenue balances: Disclosure of Revenue March 31, 2022 Current Non-Current Total $ $ $ Novo Amendment 2,580 1,328 3,908 CH License Agreement 2 1,322 1,324 NK License Agreement — 133 133 Total 2,582 2,783 5,365 December 31, 2021 Current Non-Current Total $ $ $ Novo Amendment 4,791 23 4,814 CH License Agreement 24 1,334 1,358 NK License Agreement — 136 136 Total 4,815 1,493 6,308 NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS AS AT MARCH 31, 2022 AND FOR THE THREE MONTHS ENDED MARCH 31, 2022 AND 2021 (amounts in thousands of US dollars, except share and per share data and as otherwise noted) (Unaudited)

Trade and other receivables

Trade and other receivables	3 Months Ended
	Mar. 31, 2022
Trade and other receivables	4. Trade and other receivables Disclosure of Detailed Trade and Other Receivables Explanatory March 31, 2022 December 31, 2021 $ $ Trade accounts receivable (net of expected credit losses of $ 55 55 302 877 Value-added tax 193 372 Grant receivable 146 — Other 52 65 Trade and other receivables 693 1,314 In March 2022, the Company was awarded a monetary subsidy with respect to two pre-clinical programs—namely, the Company’s development of an oral vaccine against infections with SARS-CoV-2 and the development of a product candidate for the treatment of neuromyelitis optica. The subsidy was awarded pursuant to the provisions of the German Act on Tax Incentives for Research and Development, which provides direct reimbursement of certain qualifying R&D expenditures to eligible entities. CoV-2 grant is related to R&D expenditures incurred in 2021 and during the first quarter of 2022. Neuromyelitis Optica grant is related to expenditures incurred in 2021 and during the first quarter of 2022.

Prepaid expenses and other curr

Prepaid expenses and other current assets	3 Months Ended
	Mar. 31, 2022
Prepaid expenses and other current assets	5. Prepaid expenses and other current assets Disclosure of Prepaid Expenses and Other Current Assets Explanatory March 31, 2022 December 31, 2021 $ $ Prepaid insurance — 421 Prepaid research and development 907 1,329 Other 143 22 Prepaid expenses and other current assets 1,050 1,772

Payables and accrued liabilitie

Payables and accrued liabilities	3 Months Ended
	Mar. 31, 2022
Payables and accrued liabilities	6. Payables and accrued liabilities Disclosure of Detailed Information about Payables and Accrued Liabilities Explanatory March 31, 2022 December 31, 2021 $ $ Trade accounts payable 1,022 934 Salaries, employment taxes and benefits 517 531 Accrued research and development costs 695 596 Other accrued liabilities 561 611 Payables and accrued liabilities 2,795 2,672 NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS AS AT MARCH 31, 2022 AND FOR THE THREE MONTHS ENDED MARCH 31, 2022 AND 2021 (amounts in thousands of US dollars, except share and per share data and as otherwise noted) (Unaudited)

Employee future benefits

Employee future benefits	3 Months Ended
	Mar. 31, 2022
Employee future benefits	7. Employee future benefits The change in the Company’s accrued benefit obligations is summarized as follows: DIsclosure of Net Defined Benefit Liability Asset Three months ended March 31, 2022 Year ended December 31, 2021 Pension benefit plans Other benefit plans Total Total $ $ $ $ Change in plan liabilities Balances – Beginning of the period 29,313 99 29,412 15,435 Current service cost 17 3 20 65 Interest cost 80 — 80 88 Employee Contributions 2 — 2 — Actuarial gain arising from changes in financial assumptions (3,194 ) — (3,194 ) (1,130 ) Past service cost associated with multi-employer plan — — — 16,137 Actuarial loss arising from change in current assumptions on funding of future pension increases — — — 556 Benefits paid (165 ) (1 ) (166 ) (511 ) Impact of foreign exchange rate changes (551 ) (2 ) (553 ) (1,228 ) Balances – End of the period 25,502 99 25,601 29,412 Change in plan assets Balances – Beginning of the period 11,927 — 11,927 — Presentation of plan assets as of December 31, 2021 — — — 11,963 Remeasurement of plan assets (445 ) — (445 ) — Employer contributions 12 — 12 — Employee contributions 2 — 2 — Benefits paid (57 ) — (57 ) — Impact of foreign exchange rate changes (224 ) — (224 ) (36 ) Balances – End of the period 11,215 — 11,215 11,927 Net liability of the unfunded plans 10,976 99 11,075 12,749 Net liability of the funded plans 3,311 — 3,311 4,736 Net amount recognized as Employee future benefits 14,287 99 14,386 17,485 Amounts recognized: In net loss 97 3 100 (153 ) In other comprehensive loss (3,076 ) (2 ) (3,078 ) 2,408 The calculation of the pension benefit obligation is sensitive to the discount rate assumption. Discount rates were 1.1% 1.7% NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS AS AT MARCH 31, 2022 AND FOR THE THREE MONTHS ENDED MARCH 31, 2022 AND 2021 (amounts in thousands of US dollars, except share and per share data and as otherwise noted) (Unaudited)

Share capital, warrants and oth

Share capital, warrants and other capital	3 Months Ended
	Mar. 31, 2022
Disclosure of classes of share capital [abstract]
Share capital, warrants and other capital	8. Share capital, warrants and other capital The Company has an unlimited number of authorized common shares (being voting and participating shares) with no par value, as well as an unlimited number of preferred, first and second ranking shares, issuable in series, with rights and privileges specific to each class, with no par value. 2021 On February 19, 2021, the Company completed an underwritten public offering of 20,509,746 1.45 29,739 2,837 3,076,461 1.45 1,435,682 1.8125 February 17, 2026 On February 22, 2021, the underwriter exercised the Underwriter Option in full and received 3,076,461 4,461 215,352 Aggregate gross proceeds received in connection with the February 2021 Financing totaled $ 34,200 3,221 1,897 The table presented below shows the inputs and assumptions applied to the Black-Scholes option pricing model in order to determine the fair value of these Placement agent warrants: Disclosure of Fair Value of Warrants Assumptions Explanatory Number of equivalent shares Market value per share price Weighted average exercise price Risk-free annual interest rate Expected volatility Expected life (years) Expected dividend yield ($) ($) (i) (ii) (iii) (iv) February 2021 Placement agent warrants – public offering 1,435,682 1.48 1.8125 0.58734 % 119.18 % 4.99 0.00 % February 2021 Placement agent warrants – Underwriter Option 215,352 1.48 1.8125 0.58544 % 119.57 % 4.98 0.00 % (i) Based on United States Treasury Government Bond interest rates with a term that is consistent with the expected life of the warrants. (ii) Based on the historical volatility of the Company’s stock price over the most recent period consistent with the expected life of the warrants. (iii) Based upon time to expiry from the issuance date. (iv) The Company has not paid dividends and it does not intend to pay dividends in the foreseeable future. NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS AS AT MARCH 31, 2022 AND FOR THE THREE MONTHS ENDED MARCH 31, 2022 AND 2021 (amounts in thousands of US dollars, except share and per share data and as otherwise noted) (Unaudited) During the three-month period ended March 31, 2021, certain warrant holders exercised their warrants as follows: Disclosure of Warrants Exercise Transactions Explanatory Warrants exercised (number of underlying common shares) Exercise Price Aggregate proceeds to the Company September 2019 Investor warrants 2,000,000 $ 1.65 $ 3,300 February 2020 Investor warrants 1,739,130 1.20 2,087 July 2020 Investor warrants 20,823,333 0.45 9,371 July 2020 Placement Agent warrants 1,866,667 0.5625 1,050 August 2020 Investor warrants 7,589,883 0.47 3,567 August 2020 Placement Agent warrants 869,952 0.7040625 612 34,888,965 $ 19,987 Other capital Disclosure of Detailed Information About Warrants Activity Reclassified Into Equity Explanatory Three months ended March 31, 2022 Stock options Weighted average exercise price DSUs (Number) ($) (Number) Balance – January 1, 2022 1,086,368 0.88 423,000 Granted 50,000 0.36 — Expired — — — Exercised — — — Balance – March 31, 2022 1,136,368 0.85 423,000 Year ended December 31, 2021 Stock options Weighted average exercise price DSUs (Number) ($) (Number) Balance – January 1, 2021 506,400 1.44 173,000 Granted 580,000 0.42 280,000 Expired (32 ) 590.25 — Exercised — — (30,000 ) Balance – December 31, 2021 1,086,368 0.88 423,000 NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS AS AT MARCH 31, 2022 AND FOR THE THREE MONTHS ENDED MARCH 31, 2022 AND 2021 (amounts in thousands of US dollars, except share and per share data and as otherwise noted) (Unaudited) Fair value input assumptions for US dollar stock option grants The table below shows the assumptions, or weighted average parameters, applied to the Black-Scholes option pricing model in order to determine share-based compensation costs over the life of the awards. Disclosure of Number and Weighted Average Exercise Prices of Share Options Three Months Ended Year Ended March 31, December 31 2022 2021 Expected dividend yield (a) 0.00 % 0.00 % Expected volatility (b) 115.80 % 115.80 % Risk-free annual interest rate (c) 1.23 % 1.23 % Expected life (years) (d) 5.71 5.71 Weighted average share price $ 0.42 $ 0.42 Weighted average exercise price $ 0.42 $ 0.42 Weighted average grant date fair value $ 0.35 $ 0.35 (a) The Company has not paid dividends and it does not intend to pay dividends in the foreseeable future. (b) Based on the historical volatility of the Company’s stock price over the most recent period consistent with the expected life of the stock options, as well as on future expectations. (c) Based on United States Treasury Government Bond interest rates with a term that is consistent with the expected life of the stock options. (d) Based upon historical data related to the exercise of stock options, on post-vesting employment terminations and on future expectations related to exercise behavior.

Operating expenses

Operating expenses	3 Months Ended
	Mar. 31, 2022
Operating expenses	9. Operating expenses The nature of the Company’s operating expenses from operations include the following: Disclosure of Detailed Information About Operating Expenses Explanatory Three months ended March 31, 2022 2021 $ $ Key management personnel: Salaries and short-term employee benefits 355 219 Consultant fees 17 48 Share-based compensation costs 16 10 Post-employment benefits 18 12 Key management personnel compensation 406 289 Other employees: Salaries and short-term employee benefits 415 310 Post-employment benefits 85 38 Share-based compensation costs 11 3 Other employees compensation 511 351 Cost of inventory used and services provided 79 29 Professional fees 647 580 Consulting fees 260 130 Insurance 422 227 Third-party research and development 1,975 1,147 Grants (note 4) (146 ) — Travel 43 22 Marketing services 5 97 Laboratory supplies 87 15 Other goods and services 45 19 Leasing costs (40 ) 34 Depreciation and amortization 36 36 Operating foreign exchange loss — 21 Total operating expenses 4,330 2,997 NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS AS AT MARCH 31, 2022 AND FOR THE THREE MONTHS ENDED MARCH 31, 2022 AND 2021 (amounts in thousands of US dollars, except share and per share data and as otherwise noted) (Unaudited)

Supplemental disclosure of cash

Supplemental disclosure of cash flow information	3 Months Ended
	Mar. 31, 2022
Supplemental disclosure of cash flow information	10. Supplemental disclosure of cash flow information Disclosure of Changes in Operating Assets and Liabilities Explanatory Three months ended March 31, 2022 2021 $ $ Changes in operating assets and liabilities: Trade and other receivables 474 650 Inventory (206 ) (40 ) Prepaid expenses and other current assets 711 (93 ) Payables and accrued liabilities 159 115 Taxes payable — (129 ) Deferred revenues 8 1,227 Employee future benefits (20 ) (83 ) Changes in operating assets and liabilities 1,126 1,647

Segment information

Segment information	3 Months Ended
	Mar. 31, 2022
Segment information	11. Segment information The Company operates in a single operating segment, being the biopharmaceutical segment.

Net loss per share

Net loss per share	3 Months Ended
	Mar. 31, 2022
Net loss per share	12. Net loss per share The following table sets forth pertinent data relating to the computation of basic and diluted net loss per share attributable to common shareholders. Disclosure of Earnings Per Share Three months ended March 31, 2022 2021 $ $ Net loss (2,640 ) (1,458 ) Basic weighted average number of shares outstanding 121,397,007 95,444,990 Net loss income per share (basic) (0.02 ) (0.02 ) Dilutive effect of stock options and DSUs — — Dilutive effect of warrants — — Diluted weighted average number of shares outstanding 121,397,007 95,444,990 Net loss per share (diluted) (0.02 ) (0.02 ) Items excluded from the calculation of diluted net loss per share because the exercise price was greater than the average market price of the common shares or due to their anti-dilutive effect Stock options and DSUs 1,559,368 679,400 Warrants 11,441,213 11,663,435 NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS AS AT MARCH 31, 2022 AND FOR THE THREE MONTHS ENDED MARCH 31, 2022 AND 2021 (amounts in thousands of US dollars, except share and per share data and as otherwise noted) (Unaudited) Net loss per share is calculated by dividing net loss by the weighted average number of shares outstanding during the relevant period. Diluted weighted average number of shares reflects the dilutive effect of equity instruments, such as any “in the money” stock options, DSUs and warrants. In periods with reported net losses, all stock options and warrants are deemed anti-dilutive such that basic net loss per share and diluted net loss per share are equal, and thus “in the money” stock options and warrants have not been included in the computation of net loss per share because to do so would be anti-dilutive.

Commitments

Commitments	3 Months Ended
	Mar. 31, 2022
Commitments	13. Commitments Disclosure of Finance Lease and Operating Lease by Lessee Explanatory Service and manufacturing R&D contracts TOTAL $ $ $ Less than 1 year 518 2,056 2,574 1 - 3 years 638 630 1,268 4 - 5 years 1 — 1 More than 5 years — — — Total 1,157 2,686 3,843 The Company executed various agreements including in-licensing and similar arrangements with development partners. Such agreements may require the Company to make payments on achievement of stages of development, launch or revenue milestones, although the Company generally has the right to terminate these agreements at no penalty. The Company recognizes research and development milestones as an intangible asset once it is committed to the payment, which is generally when the Company reaches a set point in the development cycle. Based on the closing exchange rates at March 31, 2022, the Company expects to pay $ 2,686 2.3 0.1 8,757 6.5 1.2 32,309 27.6 1.3 Disclosure of Research and Development and Revenue Related Milestone Payments Explanatory Future potential R&D milestone payments Future potential revenue milestone payments TOTAL $ $ $ Less than 1 year 28 — 28 1 - 3 years 111 — 111 4 - 5 years 909 — 909 More than 5 years 7,709 32,309 40,018 Total 8,757 32,309 41,066 The future payments that are disclosed represent contract payments and are not discounted and are not risk-adjusted. The development of any pharmaceutical product candidates is a complex and risky process that may fail at any stage in the development process due to a number of factors. The timing of the payments is based on the Company’s current best estimate of achievement of the relevant milestone.

Business overview (Tables)

Business overview (Tables)	3 Months Ended
	Mar. 31, 2022
Disclosure of Restatements	Disclosure of Restatements

License and supply arrangemen_2

License and supply arrangements (Tables)	3 Months Ended
	Mar. 31, 2022
Disclosure of Revenue	The following table provides a summary of deferred revenue balances: Disclosure of Revenue March 31, 2022 Current Non-Current Total $ $ $ Novo Amendment 2,580 1,328 3,908 CH License Agreement 2 1,322 1,324 NK License Agreement — 133 133 Total 2,582 2,783 5,365 December 31, 2021 Current Non-Current Total $ $ $ Novo Amendment 4,791 23 4,814 CH License Agreement 24 1,334 1,358 NK License Agreement — 136 136 Total 4,815 1,493 6,308

Trade and other receivables (Ta

Trade and other receivables (Tables)	3 Months Ended
	Mar. 31, 2022
Disclosure of Detailed Trade and Other Receivables Explanatory	Disclosure of Detailed Trade and Other Receivables Explanatory March 31, 2022 December 31, 2021 $ $ Trade accounts receivable (net of expected credit losses of $ 55 55 302 877 Value-added tax 193 372 Grant receivable 146 — Other 52 65 Trade and other receivables 693 1,314

Prepaid expenses and other cu_2

Prepaid expenses and other current assets (Tables)	3 Months Ended
	Mar. 31, 2022
Disclosure of Prepaid Expenses and Other Current Assets Explanatory	Disclosure of Prepaid Expenses and Other Current Assets Explanatory March 31, 2022 December 31, 2021 $ $ Prepaid insurance — 421 Prepaid research and development 907 1,329 Other 143 22 Prepaid expenses and other current assets 1,050 1,772

Payables and accrued liabilit_2

Payables and accrued liabilities (Tables)	3 Months Ended
	Mar. 31, 2022
Disclosure of Detailed Information about Payables and Accrued Liabilities Explanatory	Disclosure of Detailed Information about Payables and Accrued Liabilities Explanatory March 31, 2022 December 31, 2021 $ $ Trade accounts payable 1,022 934 Salaries, employment taxes and benefits 517 531 Accrued research and development costs 695 596 Other accrued liabilities 561 611 Payables and accrued liabilities 2,795 2,672

Employee future benefits (Table

Employee future benefits (Tables)	3 Months Ended
	Mar. 31, 2022
DIsclosure of Net Defined Benefit Liability Asset	DIsclosure of Net Defined Benefit Liability Asset Three months ended March 31, 2022 Year ended December 31, 2021 Pension benefit plans Other benefit plans Total Total $ $ $ $ Change in plan liabilities Balances – Beginning of the period 29,313 99 29,412 15,435 Current service cost 17 3 20 65 Interest cost 80 — 80 88 Employee Contributions 2 — 2 — Actuarial gain arising from changes in financial assumptions (3,194 ) — (3,194 ) (1,130 ) Past service cost associated with multi-employer plan — — — 16,137 Actuarial loss arising from change in current assumptions on funding of future pension increases — — — 556 Benefits paid (165 ) (1 ) (166 ) (511 ) Impact of foreign exchange rate changes (551 ) (2 ) (553 ) (1,228 ) Balances – End of the period 25,502 99 25,601 29,412 Change in plan assets Balances – Beginning of the period 11,927 — 11,927 — Presentation of plan assets as of December 31, 2021 — — — 11,963 Remeasurement of plan assets (445 ) — (445 ) — Employer contributions 12 — 12 — Employee contributions 2 — 2 — Benefits paid (57 ) — (57 ) — Impact of foreign exchange rate changes (224 ) — (224 ) (36 ) Balances – End of the period 11,215 — 11,215 11,927 Net liability of the unfunded plans 10,976 99 11,075 12,749 Net liability of the funded plans 3,311 — 3,311 4,736 Net amount recognized as Employee future benefits 14,287 99 14,386 17,485 Amounts recognized: In net loss 97 3 100 (153 ) In other comprehensive loss (3,076 ) (2 ) (3,078 ) 2,408

Share capital, warrants and o_2

Share capital, warrants and other capital (Tables)	3 Months Ended
	Mar. 31, 2022
Disclosure of classes of share capital [abstract]
Disclosure of Fair Value of Warrants Assumptions Explanatory	Disclosure of Fair Value of Warrants Assumptions Explanatory Number of equivalent shares Market value per share price Weighted average exercise price Risk-free annual interest rate Expected volatility Expected life (years) Expected dividend yield ($) ($) (i) (ii) (iii) (iv) February 2021 Placement agent warrants – public offering 1,435,682 1.48 1.8125 0.58734 % 119.18 % 4.99 0.00 % February 2021 Placement agent warrants – Underwriter Option 215,352 1.48 1.8125 0.58544 % 119.57 % 4.98 0.00 % (i) Based on United States Treasury Government Bond interest rates with a term that is consistent with the expected life of the warrants. (ii) Based on the historical volatility of the Company’s stock price over the most recent period consistent with the expected life of the warrants. (iii) Based upon time to expiry from the issuance date. (iv) The Company has not paid dividends and it does not intend to pay dividends in the foreseeable future.
Disclosure of Warrants Exercise Transactions Explanatory	Disclosure of Warrants Exercise Transactions Explanatory Warrants exercised (number of underlying common shares) Exercise Price Aggregate proceeds to the Company September 2019 Investor warrants 2,000,000 $ 1.65 $ 3,300 February 2020 Investor warrants 1,739,130 1.20 2,087 July 2020 Investor warrants 20,823,333 0.45 9,371 July 2020 Placement Agent warrants 1,866,667 0.5625 1,050 August 2020 Investor warrants 7,589,883 0.47 3,567 August 2020 Placement Agent warrants 869,952 0.7040625 612 34,888,965 $ 19,987
Disclosure of Detailed Information About Warrants Activity Reclassified Into Equity Explanatory	Disclosure of Detailed Information About Warrants Activity Reclassified Into Equity Explanatory Three months ended March 31, 2022 Stock options Weighted average exercise price DSUs (Number) ($) (Number) Balance – January 1, 2022 1,086,368 0.88 423,000 Granted 50,000 0.36 — Expired — — — Exercised — — — Balance – March 31, 2022 1,136,368 0.85 423,000 Year ended December 31, 2021 Stock options Weighted average exercise price DSUs (Number) ($) (Number) Balance – January 1, 2021 506,400 1.44 173,000 Granted 580,000 0.42 280,000 Expired (32 ) 590.25 — Exercised — — (30,000 ) Balance – December 31, 2021 1,086,368 0.88 423,000
Disclosure of Number and Weighted Average Exercise Prices of Share Options	Disclosure of Number and Weighted Average Exercise Prices of Share Options Three Months Ended Year Ended March 31, December 31 2022 2021 Expected dividend yield (a) 0.00 % 0.00 % Expected volatility (b) 115.80 % 115.80 % Risk-free annual interest rate (c) 1.23 % 1.23 % Expected life (years) (d) 5.71 5.71 Weighted average share price $ 0.42 $ 0.42 Weighted average exercise price $ 0.42 $ 0.42 Weighted average grant date fair value $ 0.35 $ 0.35 (a) The Company has not paid dividends and it does not intend to pay dividends in the foreseeable future. (b) Based on the historical volatility of the Company’s stock price over the most recent period consistent with the expected life of the stock options, as well as on future expectations. (c) Based on United States Treasury Government Bond interest rates with a term that is consistent with the expected life of the stock options. (d) Based upon historical data related to the exercise of stock options, on post-vesting employment terminations and on future expectations related to exercise behavior.

Operating expenses (Tables)

Operating expenses (Tables)	3 Months Ended
	Mar. 31, 2022
Disclosure of Detailed Information About Operating Expenses Explanatory	Disclosure of Detailed Information About Operating Expenses Explanatory Three months ended March 31, 2022 2021 $ $ Key management personnel: Salaries and short-term employee benefits 355 219 Consultant fees 17 48 Share-based compensation costs 16 10 Post-employment benefits 18 12 Key management personnel compensation 406 289 Other employees: Salaries and short-term employee benefits 415 310 Post-employment benefits 85 38 Share-based compensation costs 11 3 Other employees compensation 511 351 Cost of inventory used and services provided 79 29 Professional fees 647 580 Consulting fees 260 130 Insurance 422 227 Third-party research and development 1,975 1,147 Grants (note 4) (146 ) — Travel 43 22 Marketing services 5 97 Laboratory supplies 87 15 Other goods and services 45 19 Leasing costs (40 ) 34 Depreciation and amortization 36 36 Operating foreign exchange loss — 21 Total operating expenses 4,330 2,997

Supplemental disclosure of ca_2

Supplemental disclosure of cash flow information (Tables)	3 Months Ended
	Mar. 31, 2022
Disclosure of Changes in Operating Assets and Liabilities Explanatory	Disclosure of Changes in Operating Assets and Liabilities Explanatory Three months ended March 31, 2022 2021 $ $ Changes in operating assets and liabilities: Trade and other receivables 474 650 Inventory (206 ) (40 ) Prepaid expenses and other current assets 711 (93 ) Payables and accrued liabilities 159 115 Taxes payable — (129 ) Deferred revenues 8 1,227 Employee future benefits (20 ) (83 ) Changes in operating assets and liabilities 1,126 1,647

Net loss per share (Tables)

Net loss per share (Tables)	3 Months Ended
	Mar. 31, 2022
Disclosure of Earnings Per Share	Disclosure of Earnings Per Share Three months ended March 31, 2022 2021 $ $ Net loss (2,640 ) (1,458 ) Basic weighted average number of shares outstanding 121,397,007 95,444,990 Net loss income per share (basic) (0.02 ) (0.02 ) Dilutive effect of stock options and DSUs — — Dilutive effect of warrants — — Diluted weighted average number of shares outstanding 121,397,007 95,444,990 Net loss per share (diluted) (0.02 ) (0.02 ) Items excluded from the calculation of diluted net loss per share because the exercise price was greater than the average market price of the common shares or due to their anti-dilutive effect Stock options and DSUs 1,559,368 679,400 Warrants 11,441,213 11,663,435

Commitments (Tables)

Commitments (Tables)	3 Months Ended
	Mar. 31, 2022
Disclosure of Finance Lease and Operating Lease by Lessee Explanatory	Disclosure of Finance Lease and Operating Lease by Lessee Explanatory Service and manufacturing R&D contracts TOTAL $ $ $ Less than 1 year 518 2,056 2,574 1 - 3 years 638 630 1,268 4 - 5 years 1 — 1 More than 5 years — — — Total 1,157 2,686 3,843
Disclosure of Research and Development and Revenue Related Milestone Payments Explanatory	Disclosure of Research and Development and Revenue Related Milestone Payments Explanatory Future potential R&D milestone payments Future potential revenue milestone payments TOTAL $ $ $ Less than 1 year 28 — 28 1 - 3 years 111 — 111 4 - 5 years 909 — 909 More than 5 years 7,709 32,309 40,018 Total 8,757 32,309 41,066

Disclosure of Revenue (Details)

Disclosure of Revenue (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
IfrsStatementLineItems [Line Items]
Total Current Deferred Revenues	$ 2,582	$ 4,815
Total Deferred Revenues Non Current	2,783	1,493
Total Deferred Revenues	5,365	6,308
Novo Amendment [Member]
IfrsStatementLineItems [Line Items]
Total Current Deferred Revenues	2,580	4,791
Total Deferred Revenues Non Current	1,328	23
Total Deferred Revenues	3,908	4,814
CH License Agreement [Member]
IfrsStatementLineItems [Line Items]
Total Current Deferred Revenues	2	24
Total Deferred Revenues Non Current	1,322	1,334
Total Deferred Revenues	1,324	1,358
NK License Agreement [Member]
IfrsStatementLineItems [Line Items]
Total Current Deferred Revenues
Total Deferred Revenues Non Current	133	136
Total Deferred Revenues	$ 133	$ 136

Disclosure of Detailed Trade an

Disclosure of Detailed Trade and Other Receivables Explanatory (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Trade accounts receivable (net of expected credit losses of $55 (December 31, 2021 - $55))	$ 302	$ 877
Value-added tax	193	372
Grant receivable	146
Other	52	65
Trade and other receivables	$ 693	$ 1,314

Disclosure of Detailed Trade _2

Disclosure of Detailed Trade and Other Receivables Explanatory (Details) (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Trade accounts receivable, expected credit losses	$ 55	$ 55

Disclosure of Prepaid Expenses

Disclosure of Prepaid Expenses and Other Current Assets Explanatory (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Prepaid insurance		$ 421
Prepaid research and development	907	1,329
Other	143	22
Prepaid expenses and other current assets	$ 1,050	$ 1,772

Disclosure of Detailed Informat

Disclosure of Detailed Information about Payables and Accrued Liabilities Explanatory (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Trade accounts payable	$ 1,022	$ 934
Salaries, employment taxes and benefits	517	531
Accrued research and development costs	695	596
Other accrued liabilities	561	611
Payables and accrued liabilities	$ 2,795	$ 2,672

DIsclosure of Net Defined Benef

DIsclosure of Net Defined Benefit Liability Asset (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Change in plan liabilities
Balances – Beginning of the period	$ 29,412	$ 15,435
Current service cost	20	65
Interest cost	80	88
Employee contributions	2
Actuarial gain arising from changes in financial assumptions	(3,194)	(1,130)
Past service cost associated with multi-employer plan		16,137
Actuarial loss arising from change in current assumptions on funding of future pension increases		556
Benefits paid	(166)	(511)
Impact of foreign exchange rate changes	(553)	(1,228)
Balances – End of the period	25,601	29,412
Change in plan assets
Balances – Beginning of the period	11,927
Presentation of plan assets as of December 31, 2021		11,963
Remeasurement of plan assets	(445)
Employer contributions	12
Benefits paid	(57)
Impact of foreign exchange rate changes	(224)	(36)
Balances – End of the period	11,215	11,927
Net liability of the unfunded plans	11,075	12,749
Net liability of the funded plans	3,311	4,736
Net amount recognized as Employee future benefits	14,386	17,485
Amounts recognized:
In net loss	100	(153)
In other comprehensive loss	(3,078)	2,408
Pension defined benefit plans [member]
Change in plan liabilities
Balances – Beginning of the period	29,313
Current service cost	17
Interest cost	80
Employee contributions	2
Actuarial gain arising from changes in financial assumptions	(3,194)
Past service cost associated with multi-employer plan
Actuarial loss arising from change in current assumptions on funding of future pension increases
Benefits paid	(165)
Impact of foreign exchange rate changes	(551)
Balances – End of the period	25,502	29,313
Change in plan assets
Balances – Beginning of the period	11,927
Presentation of plan assets as of December 31, 2021
Remeasurement of plan assets	(445)
Employer contributions	12
Benefits paid	(57)
Impact of foreign exchange rate changes	(224)
Balances – End of the period	11,215	11,927
Net liability of the unfunded plans	10,976
Net liability of the funded plans	3,311
Net amount recognized as Employee future benefits	14,287
Amounts recognized:
In net loss	97
In other comprehensive loss	(3,076)
Other Benefit Plans [Member]
Change in plan liabilities
Balances – Beginning of the period	99
Current service cost	3
Interest cost
Employee contributions
Actuarial gain arising from changes in financial assumptions
Past service cost associated with multi-employer plan
Actuarial loss arising from change in current assumptions on funding of future pension increases
Benefits paid	(1)
Impact of foreign exchange rate changes	(2)
Balances – End of the period	99	99
Change in plan assets
Balances – Beginning of the period
Presentation of plan assets as of December 31, 2021
Remeasurement of plan assets
Employer contributions
Benefits paid
Impact of foreign exchange rate changes
Balances – End of the period
Net liability of the unfunded plans	99
Net liability of the funded plans
Net amount recognized as Employee future benefits	99
Amounts recognized:
In net loss	3
In other comprehensive loss	$ (2)

Business overview (Details Narr

Business overview (Details Narrative) $ in Millions	Mar. 31, 2022USD ($)
Deferred revenue long term portion	$ 1.2

Employee future benefits (Detai

Employee future benefits (Details Narrative)	Mar. 31, 2022	Dec. 31, 2021
Pension defined benefit plans [member]
IfrsStatementLineItems [Line Items]
Defined benefit obligation, discount rate	1.70%	1.10%

Disclosure of Fair Value of War

Disclosure of Fair Value of Warrants Assumptions Explanatory (Details) - $ / shares		3 Months Ended	12 Months Ended
		Mar. 31, 2022	Dec. 31, 2021
IfrsStatementLineItems [Line Items]
Market value per share price		$ 0.42	$ 0.42
Risk-free annual interest rate	[1]	1.23%	1.23%
Expected volatility	[2]	115.80%	115.80%
Expected dividend yield	[3]	0.00%	0.00%
February 2021 Placement Agent Warrants Public Offering [Member]
IfrsStatementLineItems [Line Items]
Number of equivalent shares		1,435,682
Market value per share price		$ 1.48
Weighted average exercise price		$ 1.8125
Risk-free annual interest rate	[4]	0.58734%
Expected volatility	[5]	119.18%
Expected life (years)	[6]	4 years 11 months 26 days
Expected dividend yield	[7]	0.00%
February 2021 Placement Agent Warrants Underwriter Option [Member]
IfrsStatementLineItems [Line Items]
Number of equivalent shares		215,352
Market value per share price		$ 1.48
Weighted average exercise price		$ 1.8125
Risk-free annual interest rate	[4]	0.58544%
Expected volatility	[5]	119.57%
Expected life (years)	[6]	4 years 11 months 23 days
Expected dividend yield	[7]	0.00%
[1]	Based on United States Treasury Government Bond interest rates with a term that is consistent with the expected life of the stock options.
[2]	Based on the historical volatility of the Company’s stock price over the most recent period consistent with the expected life of the stock options, as well as on future expectations.
[3]	The Company has not paid dividends and it does not intend to pay dividends in the foreseeable future.
[4]	Based on United States Treasury Government Bond interest rates with a term that is consistent with the expected life of the warrants.
[5]	Based on the historical volatility of the Company’s stock price over the most recent period consistent with the expected life of the warrants.
[6]	Based upon time to expiry from the issuance date.
[7]	The Company has not paid dividends and it does not intend to pay dividends in the foreseeable future.

Disclosure of Warrants Exercise

Disclosure of Warrants Exercise Transactions Explanatory (Details) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2021USD ($)shares$ / shares
IfrsStatementLineItems [Line Items]
Number of share options exercised in share-based payment arrangement | shares	34,888,965
Proceeds from exercise of options | $	$ 19,987
September 2019 Investor Warrants [Member]
IfrsStatementLineItems [Line Items]
Number of share options exercised in share-based payment arrangement | shares	2,000,000
Exercise Price | $ / shares	$ 1.65
Proceeds from exercise of options | $	$ 3,300
February 2020 Investor Warrants [Member]
IfrsStatementLineItems [Line Items]
Number of share options exercised in share-based payment arrangement | shares	1,739,130
Exercise Price | $ / shares	$ 1.20
Proceeds from exercise of options | $	$ 2,087
July 2020 Investor Warrants [Member]
IfrsStatementLineItems [Line Items]
Number of share options exercised in share-based payment arrangement | shares	20,823,333
Exercise Price | $ / shares	$ 0.45
Proceeds from exercise of options | $	$ 9,371
July 2020 Placement Agent Warrants [Member]
IfrsStatementLineItems [Line Items]
Number of share options exercised in share-based payment arrangement | shares	1,866,667
Exercise Price | $ / shares	$ 0.5625
Proceeds from exercise of options | $	$ 1,050
August 2020 Investor Warrants [Member]
IfrsStatementLineItems [Line Items]
Number of share options exercised in share-based payment arrangement | shares	7,589,883
Exercise Price | $ / shares	$ 0.47
Proceeds from exercise of options | $	$ 3,567
August 2020 Placement Agent Warrants [Member]
IfrsStatementLineItems [Line Items]
Number of share options exercised in share-based payment arrangement | shares	869,952
Exercise Price | $ / shares	$ 0.7040625
Proceeds from exercise of options | $	$ 612

Disclosure of Detailed Inform_2

Disclosure of Detailed Information About Warrants Activity Reclassified Into Equity Explanatory (Details)	3 Months Ended		12 Months Ended
	Mar. 31, 2022shares$ / shares	Mar. 31, 2021shares$ / shares	Dec. 31, 2021shares$ / shares
IfrsStatementLineItems [Line Items]
Shares, exercised		(34,888,965)
Employee Stock Option USD [Member]
IfrsStatementLineItems [Line Items]
Shares, balance beginning	1,086,368	506,400	506,400
Weighted average exercise price, balance beginning | $ / shares	$ 0.88	$ 1.44	$ 1.44
Shares, granted	50,000		580,000
Weighted average exercise price, granted | $ / shares	$ 0.36		$ 0.42
Shares, expired			(32)
Weighted average exercise price, expired | $ / shares			$ 590.25
Shares, exercised
Weighted average exercise price, exercised | $ / shares
Shares, balance ending	1,136,368		1,086,368
Weighted average exercise price, balance ending | $ / shares	$ 0.85		$ 0.88
Deferred Stock Units DSU [Member]
IfrsStatementLineItems [Line Items]
Shares, balance beginning	423,000	173,000	173,000
Shares, granted			280,000
Shares, expired
Shares, exercised			(30,000)
Shares, balance ending	423,000		423,000

Disclosure of Number and Weight

Disclosure of Number and Weighted Average Exercise Prices of Share Options (Details) - $ / shares		3 Months Ended	12 Months Ended
		Mar. 31, 2022	Dec. 31, 2021
Disclosure of classes of share capital [abstract]
Expected dividend yield	[1]	0.00%	0.00%
Expected volatility	[2]	115.80%	115.80%
Risk-free annual interest rate	[3]	1.23%	1.23%
Expected life (years)	[4]	5 years 8 months 15 days	5 years 8 months 15 days
Weighted average share price		$ 0.42	$ 0.42
Weighted average exercise price		0.42	0.42
Weighted average grant date fair value		$ 0.35	$ 0.35
[1]	The Company has not paid dividends and it does not intend to pay dividends in the foreseeable future.
[2]	Based on the historical volatility of the Company’s stock price over the most recent period consistent with the expected life of the stock options, as well as on future expectations.
[3]	Based on United States Treasury Government Bond interest rates with a term that is consistent with the expected life of the stock options.
[4]	Based upon historical data related to the exercise of stock options, on post-vesting employment terminations and on future expectations related to exercise behavior.

Share capital, warrants and o_3

Share capital, warrants and other capital (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands	Feb. 22, 2021	Feb. 19, 2021
Warrants [Member]
IfrsStatementLineItems [Line Items]
Proceeds from issuing common shares	$ 34,200
Cash transaction costs	3,221
Warrant liability	$ 1,897
Underwriter Option [Member]
IfrsStatementLineItems [Line Items]
Number of common shares issued, shares	215,352
Proceeds from issuing common shares	$ 4,461
Option to purchase common stock	3,076,461
Public Offering [Member]
IfrsStatementLineItems [Line Items]
Number of common shares issued, shares		20,509,746
Share price		$ 1.45
Proceeds from issuing common shares		$ 29,739
Placement agent fees and other offering expenses		$ 2,837
Public Offering [Member] | Warrants [Member]
IfrsStatementLineItems [Line Items]
Warrants Issued		1,435,682
Warrants exercise price		$ 1.8125
Warrants expiry date		Feb. 17, 2026
Underwriter Option [Member]
IfrsStatementLineItems [Line Items]
Share price		$ 1.45
Option to purchase common stock		3,076,461

Disclosure of Detailed Inform_3

Disclosure of Detailed Information About Operating Expenses Explanatory (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Salaries and short-term employee benefits	$ 355	$ 219
Consultant fees	17	48
Share-based compensation costs	16	10
Post-employment benefits	18	12
Key management personnel compensation	406	289
Salaries and short-term employee benefits	415	310
Post-employment benefits	85	38
Share-based compensation costs	11	3
Other employees compensation	511	351
Cost of inventory used and services provided	79	29
Professional fees	647	580
Consulting fees	260	130
Insurance	422	227
Third-party research and development	1,975	1,147
Grants (note 4)	(146)
Travel	43	22
Marketing services	5	97
Laboratory supplies	87	15
Other goods and services	45	19
Leasing costs	(40)	34
Depreciation and amortization	36	36
Operating foreign exchange loss		21
Total operating expenses (note 9)	$ 4,330	$ 2,997

Disclosure of Changes in Operat

Disclosure of Changes in Operating Assets and Liabilities Explanatory (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Trade and other receivables	$ 474	$ 650
Inventory	(206)	(40)
Prepaid expenses and other current assets	711	(93)
Payables and accrued liabilities	159	115
Taxes payable		(129)
Deferred revenues	8	1,227
Employee future benefits	(20)	(83)
Changes in operating assets and liabilities	$ 1,126	$ 1,647

Disclosure of Earnings Per Shar

Disclosure of Earnings Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Net loss	$ (2,640)	$ (1,458)
Basic weighted average number of shares outstanding	121,397,007	95,444,990
Net loss income per share (basic)	$ (0.02)	$ (0.02)
Dilutive effect of stock options and DSUs
Dilutive effect of warrants
Diluted weighted average number of shares outstanding	121,397,007	95,444,990
Net loss per share (diluted)	$ (0.02)	$ (0.02)
Stock options and DSUs	1,559,368	679,400
Warrants	11,441,213	11,663,435

Disclosure of Finance Lease and

Disclosure of Finance Lease and Operating Lease by Lessee Explanatory (Details) $ in Thousands	Mar. 31, 2022USD ($)
IfrsStatementLineItems [Line Items]
Total	$ 3,843
Less Than One Year [Member]
IfrsStatementLineItems [Line Items]
Total	2,574
One To Three Years [Member]
IfrsStatementLineItems [Line Items]
Total	1,268
Four To Five Years [Member]
IfrsStatementLineItems [Line Items]
Total	1
More Than Five Years [Member]
IfrsStatementLineItems [Line Items]
Total
Services And Manufacturing [Member]
IfrsStatementLineItems [Line Items]
Total	1,157
Services And Manufacturing [Member] | Less Than One Year [Member]
IfrsStatementLineItems [Line Items]
Total	518
Services And Manufacturing [Member] | One To Three Years [Member]
IfrsStatementLineItems [Line Items]
Total	638
Services And Manufacturing [Member] | Four To Five Years [Member]
IfrsStatementLineItems [Line Items]
Total	1
Services And Manufacturing [Member] | More Than Five Years [Member]
IfrsStatementLineItems [Line Items]
Total
Research And Development Contract [Member]
IfrsStatementLineItems [Line Items]
Total	2,686
Research And Development Contract [Member] | Less Than One Year [Member]
IfrsStatementLineItems [Line Items]
Total	2,056
Research And Development Contract [Member] | One To Three Years [Member]
IfrsStatementLineItems [Line Items]
Total	630
Research And Development Contract [Member] | Four To Five Years [Member]
IfrsStatementLineItems [Line Items]
Total
Research And Development Contract [Member] | More Than Five Years [Member]
IfrsStatementLineItems [Line Items]
Total

Disclosure of Research and Deve

Disclosure of Research and Development and Revenue Related Milestone Payments Explanatory (Details) $ in Thousands	Mar. 31, 2022USD ($)
IfrsStatementLineItems [Line Items]
Total	$ 41,066
Less Than One Year [Member]
IfrsStatementLineItems [Line Items]
Total	28
One To Three Years [Member]
IfrsStatementLineItems [Line Items]
Total	111
Four To Five Years [Member]
IfrsStatementLineItems [Line Items]
Total	909
More Than Five Years [Member]
IfrsStatementLineItems [Line Items]
Total	40,018
Research and Development Mile StonePayments [Member]
IfrsStatementLineItems [Line Items]
Total	8,757
Research and Development Mile StonePayments [Member] | Less Than One Year [Member]
IfrsStatementLineItems [Line Items]
Total	28
Research and Development Mile StonePayments [Member] | One To Three Years [Member]
IfrsStatementLineItems [Line Items]
Total	111
Research and Development Mile StonePayments [Member] | Four To Five Years [Member]
IfrsStatementLineItems [Line Items]
Total	909
Research and Development Mile StonePayments [Member] | More Than Five Years [Member]
IfrsStatementLineItems [Line Items]
Total	7,709
Revenue Related Mile StonePayments [Member]
IfrsStatementLineItems [Line Items]
Total	32,309
Revenue Related Mile StonePayments [Member] | Less Than One Year [Member]
IfrsStatementLineItems [Line Items]
Total
Revenue Related Mile StonePayments [Member] | One To Three Years [Member]
IfrsStatementLineItems [Line Items]
Total
Revenue Related Mile StonePayments [Member] | Four To Five Years [Member]
IfrsStatementLineItems [Line Items]
Total
Revenue Related Mile StonePayments [Member] | More Than Five Years [Member]
IfrsStatementLineItems [Line Items]
Total	$ 32,309

Commitments (Details Narrative)

Commitments (Details Narrative) $ in Thousands, € in Millions, £ in Millions	3 Months Ended
	Mar. 31, 2022USD ($)	Mar. 31, 2022EUR (€)	Mar. 31, 2022GBP (£)
IfrsStatementLineItems [Line Items]
Potential milestone payments description	the Company expects to pay $2,686, including $2,548 (€2.3 million), and $138 (£0.1 million), in R&D contracts and up to $8,757, including $7,248 (€6.5 million) and $1,509 (£1.2 million), in R&D milestone payments and up to $32,309, including $30,669 (€27.6 million) and $1,640 (£1.3 million), in revenue related milestone payments.	the Company expects to pay $2,686, including $2,548 (€2.3 million), and $138 (£0.1 million), in R&D contracts and up to $8,757, including $7,248 (€6.5 million) and $1,509 (£1.2 million), in R&D milestone payments and up to $32,309, including $30,669 (€27.6 million) and $1,640 (£1.3 million), in revenue related milestone payments.	the Company expects to pay $2,686, including $2,548 (€2.3 million), and $138 (£0.1 million), in R&D contracts and up to $8,757, including $7,248 (€6.5 million) and $1,509 (£1.2 million), in R&D milestone payments and up to $32,309, including $30,669 (€27.6 million) and $1,640 (£1.3 million), in revenue related milestone payments.
Research and Development Contracts [Member]
IfrsStatementLineItems [Line Items]
Potential milestone payments	$ 2,686	€ 2.3	£ 0.1
Research and Development Mile StonePayments [Member]
IfrsStatementLineItems [Line Items]
Potential milestone payments	8,757	6.5	1.2
Revenue Related Mile StonePayments [Member]
IfrsStatementLineItems [Line Items]
Potential milestone payments	$ 32,309	€ 27.6	£ 1.3